Arushi Dhar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arushi Dhar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Abena Appiah-Kubi
Department of Pediatric Hematology/Oncology & Cellular Therapy, Northwell Health, New York; and Division of Hematology/Oncology and Cellular Therapy, Cohen Children's Medical Center, New York, United States
2 shared publications Banu Aygun
Division of Pediatric Hematology/Oncology/Cellular Therapy, Cohen Children’s Medical Center, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY; and
1 shared publication- Banu Aygun
Northwell New Hyde Park New York USA
1 shared publication Danielle Aronowitz
Hofstra Northwell School of Medicine, Hempstead, New York
1 shared publication- Danielle T. Fisenne
Department of Pediatrics, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, USA
1 shared publication David Benjamin Meyer
Department of Pediatric Cardiothoracic Surgery, Cohen Children's Medical Center of New York, New Hyde Park, New York
1 shared publication
Latest Publications
- Open Access
- 31 May 2024
- Published by IntechOpen
Cardiopulmonary Complications of Sickle Cell Disease in Children
Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy leading to hemolysis, increased endothelial adhesion, inflammation, and vasculopathy. While most children with SCD have normal pulmonary function, lung capacity and expiratory flows are lower compared to age- and racially matched controls. Airway obstruction dominates in children, with restrictive ventilatory defects becoming more prevalent in adolescents and young adults. Decreased pulmonary function, physician-diagnosed asthma, airway hyperresponsiveness, wheezing, and sleep-disordered breathing are associated with more frequent episodes of acute chest syndrome and vaso-occlusive crisis. Chronic lung disease, thromboembolism, hypoxemia, and sleep-disordered breathing are associated with the development of pulmonary hypertension and ventricular dysfunction which carry significant morbidity and mortality risk in adults. Most treatments for cardiopulmonary complications of SCD are based on guidelines developed for the general population. Although most guidelines do not recommend routine screening of asymptomatic children, patients with cardiopulmonary symptoms should be monitored and treated by subspecialists in a multidisciplinary setting. Disease modifying treatments such as hydroxyurea are attenuating some of the cardiopulmonary complications in SCD. More studies need to be done to assess the effects of newer disease modifying treatments targeting hemolysis and decreasing endothelial adhesion.
- 31 May 2024
- Published by IntechOpen
Open AccessCardiopulmonary Complications of Sickle Cell Disease in Children
Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy leading to hemolysis, increased endothelial adhesion, inflammation, and vasculopathy. While most children with SCD have normal pulmonary function, lung capacity and expiratory flows are lower compared to age- and racially matched controls. Airway obstruction dominates in children, with restrictive ventilatory defects becoming more prevalent in adolescents and young adults. Decreased pulmonary function, physician-diagnosed asthma, airway hyperresponsiveness, wheezing, and sleep-disordered breathing are associated with more frequent episodes of acute chest syndrome and vaso-occlusive crisis. Chronic lung disease, thromboembolism, hypoxemia, and sleep-disordered breathing are associated with the development of pulmonary hypertension and ventricular dysfunction which carry significant morbidity and mortality risk in adults. Most treatments for cardiopulmonary complications of SCD are based on guidelines developed for the general population. Although most guidelines do not recommend routine screening of asymptomatic children, patients with cardiopulmonary symptoms should be monitored and treated by subspecialists in a multidisciplinary setting. Disease modifying treatments such as hydroxyurea are attenuating some of the cardiopulmonary complications in SCD. More studies need to be done to assess the effects of newer disease modifying treatments targeting hemolysis and decreasing endothelial adhesion.
- Open Access
- 30 April 2022
- Published by Springer Nature in Cureus
- Vol. 14 (4) , e24623
Feeding Difficulties Following Vascular Ring Repair: A Contemporary Narrative Review
Vascular rings are congenital abnormalities of the aortic arch vascular system that compress the trachea and esophagus. A review of long-term outcomes suggests that chronic feeding difficulties can persist following surgical repair of vascular rings. Previous reports of postoperative vascular ring division outcomes indicate that chronic esophageal symptoms may persist following repair, though most available data focuses on persistent respiratory symptoms. It is therefore the aim of this article to summarize and organize recent evidence reporting the frequency, presentation, and management of feeding difficulties following vascular ring repair in pediatric patients. Pathophysiologic mechanisms for postoperative esophageal symptoms may include residual compression from an unresected diverticulum of Kommerell or delayed repair leading to chronic esophageal dysmotility despite correction of esophageal compression. Guidance on the management of feeding difficulties following vascular ring repair is limited. The authors describe success in one case with nasogastric tube feeding and interdisciplinary evaluation. Consensus regarding the management of feeding difficulty following vascular ring repair is needed.
- 30 April 2022
- Published by Springer Nature in Cureus
- Vol. 14 (4) , e24623
Open AccessFeeding Difficulties Following Vascular Ring Repair: A Contemporary Narrative Review
Vascular rings are congenital abnormalities of the aortic arch vascular system that compress the trachea and esophagus. A review of long-term outcomes suggests that chronic feeding difficulties can persist following surgical repair of vascular rings. Previous reports of postoperative vascular ring division outcomes indicate that chronic esophageal symptoms may persist following repair, though most available data focuses on persistent respiratory symptoms. It is therefore the aim of this article to summarize and organize recent evidence reporting the frequency, presentation, and management of feeding difficulties following vascular ring repair in pediatric patients. Pathophysiologic mechanisms for postoperative esophageal symptoms may include residual compression from an unresected diverticulum of Kommerell or delayed repair leading to chronic esophageal dysmotility despite correction of esophageal compression. Guidance on the management of feeding difficulties following vascular ring repair is limited. The authors describe success in one case with nasogastric tube feeding and interdisciplinary evaluation. Consensus regarding the management of feeding difficulty following vascular ring repair is needed.
- Open Access
- 1 November 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (21) , 4406-4412
Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy
Cardiac abnormalities such as left ventricular hypertrophy, left ventricular dilation, and pulmonary hypertension in sickle cell anemia have been previously described. Hydroxyurea, a disease-modifying therapy for sickle cell anemia, has been used for several decades. Longitudinal assessment of echocardiographic abnormalities in children and young adults with sickle cell anemia receiving hydroxyurea therapy is lacking. The goal of this retrospective study was to determine the prevalence of echocardiographic abnormalities in children and young adults with sickle cell anemia and to examine the effects of hydroxyurea on reverse cardiac remodeling. We reviewed the records of patients with sickle cell anemia who underwent routine cardiac screening at Cohen Children’s Medical Center between 2010 and 2017, followed by retrospective longitudinal analysis of echocardiograms performed on patients receiving treatment with hydroxyurea. Data on a total of 100 patients with sickle cell anemia were analyzed; 60 (60%) were being treated with hydroxyurea. Twenty-five (41.6%) of the patients on hydroxyurea had been treated for 1 year. Serial echocardiograms of patients receiving hydroxyurea were then analyzed. Left ventricular dilation and hypertrophy improved significantly with hydroxyurea treatment. In addition, the left ventricular volume and mass correlated negatively with duration of treatment with hydroxyurea. Our study provides evidence that prolonged hydroxyurea therapy may lead to reverse cardiac remodeling. Future studies should attempt to follow up this patient cohort for a longer duration.
- 1 November 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (21) , 4406-4412
Open AccessLongitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy
Cardiac abnormalities such as left ventricular hypertrophy, left ventricular dilation, and pulmonary hypertension in sickle cell anemia have been previously described. Hydroxyurea, a disease-modifying therapy for sickle cell anemia, has been used for several decades. Longitudinal assessment of echocardiographic abnormalities in children and young adults with sickle cell anemia receiving hydroxyurea therapy is lacking. The goal of this retrospective study was to determine the prevalence of echocardiographic abnormalities in children and young adults with sickle cell anemia and to examine the effects of hydroxyurea on reverse cardiac remodeling. We reviewed the records of patients with sickle cell anemia who underwent routine cardiac screening at Cohen Children’s Medical Center between 2010 and 2017, followed by retrospective longitudinal analysis of echocardiograms performed on patients receiving treatment with hydroxyurea. Data on a total of 100 patients with sickle cell anemia were analyzed; 60 (60%) were being treated with hydroxyurea. Twenty-five (41.6%) of the patients on hydroxyurea had been treated for 1 year. Serial echocardiograms of patients receiving hydroxyurea were then analyzed. Left ventricular dilation and hypertrophy improved significantly with hydroxyurea treatment. In addition, the left ventricular volume and mass correlated negatively with duration of treatment with hydroxyurea. Our study provides evidence that prolonged hydroxyurea therapy may lead to reverse cardiac remodeling. Future studies should attempt to follow up this patient cohort for a longer duration.
- 1 September 2017
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 104 (3) , e269-e270
Surgical Angioplasty of Stenotic Left Main Coronary Artery 15 Years After ALCAPA Repair
- 1 September 2017
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 104 (3) , e269-e270
Surgical Angioplasty of Stenotic Left Main Coronary Artery 15 Years After ALCAPA Repair